Welsh Biotech Draig Emerges with $140m in Financing

Welsh biotech Draig emerges with $140m in financing

Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases

Welsh university spinout in huge £100m plus investment for its pioneering neuropsychiatric disorder therapies

Draig Therapeutics said the funding will support clinicial trials as it aims to move closer to commercialisation

£107m boost for Cardiff spin-out pioneering neuropsychiatric drugs

Cardiff University spin-out Draig Therapeutics has been awarded £107m ($140m) investment from leading international venture investors to advance the development of novel therapies for major neuropsychiatric disorders such as major depressive disorder The research is based on the expertise of Professor John Atack and Professor Simon Ward from Cardiff University’s Medicines Discovery Institute, and Draig Therapeutics will translate the latest rese…

Ropes & Gray Represents Sanofi in Investment in Draig Therapeutics’ $140 million Series A Financing

Ropes & Gray represented Sanofi in its investment in Draig Therapeutics’ $140 million Series A financing. Draig Therapeutics is a Cardiff-based clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, launching from stealth. Draig Therapeutics was formed through a partnership with Cardiff University’s Medicines Discovery Institute. The Ropes & Gray team included emerging companies and venture capital counsel David D…

Draig Therapeutics Secures $140M Series A - USA Herald

Draig Therapeutics Ltd., a rising star in neuropsychiatric drug development, has closed a $140 million Series A financing round, the company announced Wednesday, marking a monumental leap toward revolutionizing treatments for severe depression. The financing, led by New York-based Access Biotechnology, positions Draig among the most heavily backed biotech startups in Europe this year. The round drew further support from SV Health Investors, Sano…

Sanofi-backed Welsh biotech secures $140M for neuropsychiatry pipeline

A UK biotech named after the Welsh word for dragon has emerged from stealth with a Phase 2-ready candidate for depression and an oversubscribed Series A fundraise backed by the venture arm of Sanofi. ...